|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 9,365,500
Summary
U.S. Patent 9,365,500, granted on June 7, 2016, to Global Blood Therapeutics, Inc., pertains to a method of treating sickle cell disease through the administration of voxelotor (formerly GBT440). The patent claims cover the compound itself, its preparation, and therapeutic methods utilizing this compound. The scope of the patent encompasses chemical structures, formulations, and methods of use, positioning it as a critical patent in the field of hemoglobinopathies, specifically sickle cell disease. The patent landscape surrounding this patent is notable for its focus on hemoglobin modifiers and other therapeutics targeting sickle cell pathology, with several related patents filed by competitors or companies engaged in sickle cell treatment.
This report examines the patent claims in detail, assesses the scope of protection, explores related prior art and patent families in the therapeutic space, and analyzes the patent landscape's strategic implications.
1. Patent Overview and Claim Analysis
Patent Scope
- Title: Use of Voxelotor (GBT440) for the Treatment of Sickle Cell Disease
- Patent Number: 9,365,500
- Grant Date: June 7, 2016
- Applicant: Global Blood Therapeutics, Inc.
- Field: Medicinal chemistry, hematology, pharmacology
Main Claims Summary
| Claim No. |
Type |
Scope Summary |
Legal Significance |
| 1 |
Independent |
Method of increasing hemoglobin affinity for oxygen by administering a compound having a specific chemical structure (voxelotor). |
Core therapeutic claim covering treatment method, providing broad coverage for use of the compound in sickle cell therapy. |
| 2 |
Dependent |
Specifies the compound characterized by specific substitutions on the oxazolone ligand core. |
Narrower, limits scope to particular chemical variants. |
| 3-4 |
Dependent |
Describes pharmaceutical compositions and dosages. |
Protection over specific formulations and dosage regimes. |
| 5-8 |
Dependent |
Alternative specific embodiments, such as dosing frequency and administration route. |
Extends legal coverage to various administration methods. |
Claim Language Sample (Claim 1):
"A method of increasing oxygen affinity of hemoglobin in a subject comprising administering to the subject a therapeutically effective amount of a compound represented by the structure —"
(representation of voxelotor's chemical structure omitted for brevity).
Claims Analysis
- Broadness: Claim 1 is broad, covering any method of increasing hemoglobin oxygen affinity using the compound, not limited by disease indication or administration method.
- Narrower Claims: Subsequent claims specify chemical structures, formulations, and dosing, constricting the scope but providing fallback positions depending on patent validity challenges.
- Claim Dependencies: Depend heavily on the core concept of using voxelotor for sickle cell or related hemoglobinopathies.
2. Chemical and Methodological Scope
Chemical Claims
| Chemical Structure |
Specific Variations |
Functional Group Modifications |
Coverage |
| Oxazolone core |
Substituted aromatic groups |
Amine, hydroxyl, methoxy groups |
Variants designed for optimal hemoglobin affinity modulation |
Method Claims
| Indications |
Dosing Regimes |
Route of Administration |
Claims |
| Sickle cell disease |
Daily, weekly, escalating doses |
Oral, intravenous |
Treatment methods, dose ranges from 600 mg BID to 1200 mg QD |
Implications of the Claims
- The broad chemical and therapeutic claims give Global Blood Therapeutics, Inc. a comprehensive patent barrier.
- The combination of method and composition claims ensures maximum protection against similar therapeutics.
- Limitations are generally related to specific chemical structures, doses, and formulations.
3. Patent Landscape Analysis
Key Patent Families and Related Patents
| Patent Family / Patent |
Filing Date |
Assignee / Applicant |
Focus |
Status |
| WO2014159018 (PCT) |
March 4, 2014 |
Global Blood Therapeutics |
Composition of voxelotor, method of use |
Published, pending national phase |
| US20160105537A1 |
July 9, 2014 |
GBT |
Pharmaceutical formulations, dosing |
Application published |
| EP2818444B1 |
April 8, 2020 |
GBT |
Method of treating sickle cell with voxelotor |
Granted |
| US20160228359 |
December 8, 2014 |
GBT |
Alternative compounds targeting hemoglobin |
Application |
Key Points
- Global Blood Therapeutics owns multiple patent applications covering various aspects of voxelotor, including formulations, dosing, and methods.
- Overlapping claims exist in the US, Europe, and PCT filings, creating a broad international patent family.
- Related patents by competitors tend to focus on different chemical classes, such as allosteric hemoglobin modifiers or other sickle cell therapeutics.
Competitive Patent Landscape
| Competitors / Entities |
Notable Patents |
Focus |
Status |
| Novartis |
WO2016208587 (Hemoglobin modifiers) |
Hemoglobin shifting agents |
Pending/Published |
| Novo Nordisk |
WO2017077253 |
Sickle cell treatment compositions |
Pending |
| Diffusion Pharmaceuticals |
US Patents on gas transport |
Alternative approaches |
Granted |
Patentability Challenges and Opportunities
- Similarity to prior art can be contested by demonstrating inventive step in voxelotor's chemical structure or method of use.
- The specificity of claims (chemical structure and dosing) provides some defensibility.
- Combination or formulation patents could extend protection.
4. Strategic Considerations
Strengths of the Patent
- Wide coverage of voxelotor's therapeutic uses and formulations.
- Multiple dependent claims that protect various embodiments.
- International patent filings covering key markets.
Weaknesses and Risks
- Potential for design-around through alternative hemoglobin modulators.
- Patent expiration expected around 2036 (20-year patent term from 2016), limiting long-term exclusivity.
- Prior art in hemoglobin modulation may threaten broad claims.
Patent Enforcement and Market Impact
- The patent supports a strong market position for GBT's commercialized drug Oxbryta (voxelotor).
- The patent's scope discourages competitors from developing similar hemoglobin-targeted therapies.
5. Comparative Analysis with Similar Patents
| Aspect |
U.S. Patent 9,365,500 |
Patent X (e.g., Novartis WO2016208587) |
Implication |
| Chemical Focus |
Voxelotor (oxazolone derivative) |
Allosteric hemoglobin modifiers |
Different chemical classes may avoid infringement |
| Therapeutic Claim Scope |
Hemoglobin oxygen affinity modification |
Hemoglobin shifting agents |
Varying breadth; potential cross-claims |
| Formulation Claims |
Oral, IV |
Various delivery systems |
Formulations vary as a strategy for extension |
Additional Insights
- Patent citations: The patent references foundational hemoglobin chemistry and prior sickle cell patents, indicating a comprehensive patent prosecution.
- Legal status: No reported opposition in major jurisdictions, but potential for patent challenges remains, especially based on obviousness or prior art.
- Regulatory linkage: The patent complements FDA approval for Oxbryta (voxelotor), reinforcing its commercial value.
Key Takeaways
- U.S. Patent 9,365,500 provides robust and comprehensive protection for voxelotor, covering its chemical structure, formulations, and methods of use for sickle cell disease.
- The broad claims and international portfolio position GBT favorably in defending market exclusivity.
- The patent landscape features multiple related filings by GBT and competitors, with strategic implications for formulation, dosing, and chemical variation patents.
- The expiration date around 2036 offers extended market presence, but innovation around alternative hemoglobin modifiers could pose future competition.
- Enforcement and patent robustness in key jurisdictions are crucial for maintaining market dominance.
FAQs
Q1: What is the primary therapeutic application covered by U.S. Patent 9,365,500?
A: The patent primarily covers the treatment of sickle cell disease by increasing hemoglobin's oxygen affinity using voxolotor.
Q2: How broad are the chemical claims in this patent?
A: The claims encompass voxelotor’s specific chemical structure as well as various substituted derivatives, with scope extending to formulations and dosing methods.
Q3: Are there any notable patent challenges or disputes related to this patent?
A: As of now, no publicized litigations or oppositions; however, patent validity could be challenged on grounds such as obviousness or prior art.
Q4: How does this patent fit into the broader patent landscape for sickle cell therapeutics?
A: It is part of a growing patent cluster that covers hemoglobin modifiers, with competitors filing their own composition and use patents to carve market niches.
Q5: When is the patent expected to expire, and what does this imply for exclusivity?
A: Expected expiration is around 2036, after which generic competition could emerge, potentially diminishing exclusivity unless extended via new patents or formulations.
References
[1] U.S. Patent 9,365,500, "Use of Voxelotor (GBT440) for the Treatment of Sickle Cell Disease," granted June 7, 2016.
[2] WO2014159018, "Hemoglobin Modulators," PCT application by GBT, March 4, 2014.
[3] FDA Approval announcement for Oxbryta (voxelotor), 2019.
[4] Patent landscape reports on sickle cell disease therapeutics, 2020-2022.
[5] European Patent EP2818444B1, "Method of Treating Sickle Cell Disease," April 8, 2020.
More… ↓
⤷ Start Trial
|
